Insights from Dr. Debasis Panigrahi, Pediatric Neurologist on the Exome Max Test скачать в хорошем качестве

Insights from Dr. Debasis Panigrahi, Pediatric Neurologist on the Exome Max Test

In this video, Dr. Debasis Panigrahi, a Pediatric Neurologist at Jagannath Hospital, Bhubaneshwar, shares how the Exome Max test offered comprehensive gene coverage, helping him gain deeper insights into the genetic factors involved in his patient's condition. The Exome Max, India's leading Exome test, stands out with its high diagnostic yield, covering approximately 99% of exons. This makes it an invaluable tool for connecting clinical symptoms with molecular diagnoses. It ensures extensive coverage of genes associated with diseases, including 100% mitochondrial genome coverage, specialized probes for detecting SNVs and CNVs, and coverage of alternative gene transcripts (MANE, GENCODE, REFSEQ). The test also identifies pathogenic variants in non-coding regions. At MedGenome, we are dedicated to empowering clinicians with accurate diagnostics and offering affordable testing solutions for patients. Our mission is to enhance the understanding and management of genetic conditions, inherited diseases, genetic cancer, and endocrine disorders. With advanced testing solutions like the Exome Max test, we aim to deliver the transformative potential of whole exome sequencing to improve health outcomes. --------------------------------------------- 🩺Book Genetic Counseling session with our experts here: https://diagnostics.medgenome.com/ ✅Explore Our Resources: Blogs: https://diagnostics.medgenome.com/blog/ Patient Stories: https://diagnostics.medgenome.com/pat... Press Media Mentions: https://diagnostics.medgenome.com/press/ 👍Follow and Like us on: Instagram:   / medgenome   Facebook:   / medgenomelabs   Twitter: https://x.com/medgenomelabs LinkedIn:   / medgenomelabs   🤝Connect With Us: Email: [email protected] Toll-free number: 1800 296 9696 ⬇️Download Our Application: Android: https://bit.ly/3yYVvAb iOS: https://bit.ly/4cxRikU #Exome #WholeExomeSequencing #PediatricNeurologist #WholeGenomeSequencingTest #ExomeMaxTest #MedGenome #GeneticTesting #GenomicResearch #PrecisionMedicine #InheritedDiseases #GeneticDiagnosis #MolecularTesting --------------------------------------------- About MedGenome MedGenome is a global leader in genetic testing services, genomics research, and drug discovery solutions. Since 2013, we have been committed to delivering world-class genomic solutions with precision and accuracy, empowering every individual to manage their health better. We are proud to be the only CAP-accredited genetic testing lab in India, offering 1300+ genetic tests backed by the latest and most advanced technologies available worldwide. MedGenome is dedicated to providing the best precision testing solutions for quicker and smarter diagnosis of complex diseases. Our Mission We are on a mission to democratize access to quality and affordable genetic solutions, serving over 4 billion people for their healthcare needs through the power of genetic testing. Our Expertise We operate Southeast Asia's largest CAP-accredited Next Generation Sequencing (NGS) lab, equipped with cutting-edge genome sequencing platforms such as Illumina’s NovaSeq, HiSeq X, MiSeq, and more. Our team consists of expert molecular biologists, geneticists, data scientists, and bioinformaticians driving our genomics research. As a firm believer in quality, MedGenome adheres to the highest international standards in our services and has obtained the prestigious CAP accreditation for our main lab in Bangalore. At MedGenome, we continue to push the boundaries of genetic research, providing insights into complex diseases and driving innovation in personalized medicine. --------------------------------------------- Disclaimer: The content provided in this video is intended solely for educational purposes. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have any concerns, please consult a qualified healthcare provider. MedGenome accepts no liability for individual interpretations of the content, although it is accurate to the best of our knowledge at the time of publication.